As RNA therapeutics evolve far beyond their vaccine origins, a new generation of scientists and manufacturers is rethinking how to produce these complex medicines safely, efficiently, and at scale.
Scientists at California-based Codexis started working on mRNA technology years before the COVID-19 vaccines raised awareness of this approach. Despite the success of these vaccines, enzymes used to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback